These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20053942)

  • 1. Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.
    Chen JL; Morgan AJ; Stewart-Jones G; Shepherd D; Bossi G; Wooldridge L; Hutchinson SL; Sewell AK; Griffiths GM; van der Merwe PA; Jones EY; Galione A; Cerundolo V
    J Immunol; 2010 Feb; 184(4):1829-1839. PubMed ID: 20053942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
    Irving M; Zoete V; Hebeisen M; Schmid D; Baumgartner P; Guillaume P; Romero P; Speiser D; Luescher I; Rufer N; Michielin O
    J Biol Chem; 2012 Jun; 287(27):23068-78. PubMed ID: 22549784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate.
    Dutoit V; Guillaume P; Ayyoub M; Hesdorffer CS; Luescher IF; Valmori D
    J Immunol; 2003 May; 170(10):5110-7. PubMed ID: 12734357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
    J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
    J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2D Kinetic Analysis of TCR and CD8 Coreceptor for LCMV GP33 Epitopes.
    Kolawole EM; Andargachew R; Liu B; Jacobs JR; Evavold BD
    Front Immunol; 2018; 9():2348. PubMed ID: 30374353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
    Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response.
    Reichstetter S; Ettinger RA; Liu AW; Gebe JA; Nepom GT; Kwok WW
    J Immunol; 2000 Dec; 165(12):6994-8. PubMed ID: 11120826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.
    Purbhoo MA; Sutton DH; Brewer JE; Mullings RE; Hill ME; Mahon TM; Karbach J; Jäger E; Cameron BJ; Lissin N; Vyas P; Chen JL; Cerundolo V; Jakobsen BK
    J Immunol; 2006 Jun; 176(12):7308-16. PubMed ID: 16751374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
    Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
    J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
    Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
    Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.
    Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y
    J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.